RANI
vs
S&P 500
RANI
S&P 500
Over the past 12 months, RANI has underperformed S&P 500, delivering a return of -25% compared to the S&P 500's +12% growth.
Stocks Performance
RANI vs S&P 500
Performance Gap
RANI vs S&P 500
Performance By Year
RANI vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Rani Therapeutics Holdings Inc
Glance View
Rani Therapeutics Holdings, Inc. operates as a clinical stage bio-therapeutics company providing technologies to enable the development of orally administered biologics. The company is headquartered in San Jose, California and currently employs 114 full-time employees. The company went IPO on 2021-07-30. The Company’s technologies enable the development of orally administered biologics. The firm has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which delivers any drug, including molecules, such as peptides, proteins and antibodies. The RaniPill capsule delivers up to a three micrograms (mg) dose of the drug with high bioavailability. Its capsule includes a coating that is designed to withstand stomach acid but dissolves in the jejunum portion of the small intestine. The Company’s product candidate RaniPill capsule is in Phase I clinical trial. The Company’s RaniPill capsule is delivering a variety of biological therapeutics. Its pipeline includes core product candidate programs, such as RT-101, RT-105, RT-102, RT-109 and RT-110. The firm manufactures and assembles RaniPill capsules at its facilities in San Jose and Milpitas, California.
